Aveo Kidney Cancer Drug May Need More Study, FDA Says

Aveo Pharmaceuticals Inc. fell the most in three years after U.S. regulators said its lead product candidate, a kidney cancer drug, may need another clinical trial to assess the benefit.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.